## CHUGAI PHARMACEUTICAL CO LTD

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock



## **Company Profile**

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Financial figures						
	20	2024 2023		23 2022		22
Financial figures	Assets Liabilities and equity		Assets Liabilities and equity		Assets Liabilities and equity_	
Current assets	-		1,366,426,000,000		1,336,537,000,000	
Common stock capital		-		73,202,000,000		73,202,000,000
Fixed assets	-		566,121,000,000		533,221,000,000	
Equity capital of a company		-		1,625,580,000,000		1,424,387,000,000
Cash and cash equivalents	-		458,674,000,000		222,169,000,000	
Accrued liabilities		-		5,739,000,000		6,067,000,000
Other assets	-		-		-	
Current liabilities		-		288,217,000,000		423,730,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		-		18,749,000,000		21,641,000,000
Different income		-		-		-
Other liabilities		-		743,000,000		813,000,000
Total assets	-	-	1,932,547,000,000	1,932,547,000,000	1,869,758,000,000	1,869,758,000,000

Balance notes			
	2024	2023	2022
Accounting standard	-	IFRS	IFRS
Employees	-	7,604	7,771
Equity ratio	-%	84.12%	76.18%
Debt-equity ratio	-%	18.88%	31.27%

Others			
	2024	2023	2022
Tax Expense Rate	-%	26.67%	29.51%

## **CHUGAI PHARMACEUTICAL CO LTD**

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock

Income statement			
	2024	2023	2022
Turnover	-	1,111,367,000,000	1,259,946,000,000
Net income	-	325,472,000,000	374,429,000,000
EBIT	-	2,741,175,000	3,292,472,800
Operating income before taxes	-	443,821,000,000	531,166,000,000
Cash Flow	-	411,326,000,000	244,335,000,000
Net interest income	-	1,696,000,000	122,000,000
Research and development expenses	-	164,764,000,000	148,360,000,000
Income taxes	-	118,349,000,000	156,737,000,000
Result from investments in subsidaries, associates and other	-	0	0
Revenues per employee	-	906,165	1,005,233

<b>Board of Directors</b>		
01 : 1 - 1 - 5		
Christoph Franz	Member of Supervisory Board	
James Sabry	Member of Supervisory Board	
Iwaaki Taniguchi	Member of Supervisory Board	
Mariko Momoi	Member of Supervisory Board	
Masayuki Oku	Member of Supervisory Board	
Motoo Ueno	Member of Supervisory Board	
William Anderson	Member of Supervisory Board	
Yoichiro Ichimaru	Member of Supervisory Board	

Members of Management Board		
Osamu Okuda	Chairman of Managing Board	
Hitoshi Ikura	Member of Executive Committee	
Iwaaki Taniguchi	Member of Executive Committee	
Junichi Ebihara	Member of Executive Committee	
Shinji Hidaka	Member of Executive Committee	
Tetsuya Yamaguchi	Member of Executive Committee	
Yoshiyuki Yano	Member of Executive Committee	